eCAM Advance Access originally published online on April 20, 2005
eCAM 2005 2(2):223-226; doi:10.1093/ecam/neh086
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brief Communication |
Isolation of CYP3A4 Inhibitors from the Black Cohosh (Cimicifuga racemosa)
Graduate School of Natural Science and Technology, Kanazawa University Kakuma-machi, Kanazawa 920-1192, Japan
Recent investigation on drug interaction has shown that some foods and herbal medicines increase the oral availability of a variety of CYP3A4 substrates, which is caused by the reduction of CYP3A4 in intestinal epithelium. During the course of our investigation on CYP3A4 interaction, we found that the commercially available dietary supplement made from black cohosh (Cimicifuga racemosa) showed CYP3A4 inhibition. Black cohosh has been used for the treatment of menopausal and post-menopausal symptoms as a dietary supplement. Bioassay-guided isolation from the supplement afforded six active principles, which were identified as cycloartanoid triterpene glycosides.
Keywords: black cohosh – Cimicifuga racemosa – CYP3A4 – cytochrome P450 – inhibition – triterpene glycoside
*For reprints and all correspondence: Tomihisa Ohta, Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192 Japan. Tel: +81-76-234-4468; Fax: +81-76-264-6241; E-mail: ohta{at}p.kanazawa-u.ac.jp
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
N. M. Patel and R. M. Derkits Possible Increase in Liver Enzymes Secondary to Atorvastatin and Black Cohosh Administration Journal of Pharmacy Practice, August 1, 2007; 20(4): 341 - 346. [Abstract] [PDF] |
||||
![]() |
B. Gurley, M. A. Hubbard, D. K. Williams, J. Thaden, Y. Tong, W. B. Gentry, P. Breen, D. J. Carrier, and S. Cheboyina Assessing the Clinical Significance of Botanical Supplementation on Human Cytochrome P450 3A Activity: Comparison of a Milk Thistle and Black Cohosh Product to Rifampin and Clarithromycin J. Clin. Pharmacol., February 1, 2006; 46(2): 201 - 213. [Abstract] [Full Text] [PDF] |
||||
E-letters:
Read all E-letters
- No characterisation of the extract and questionable in-vivo correlation.
- Beat Meier, et al.
- Evidence-based Complementary and Alternative Medicine, 12 Aug 2005 [Full text]

